UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2009

BIOANALYTICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

Indiana
  
0-23357
  
35-1345024
(State or other
jurisdiction of
incorporation or
organization)
  
(Commission File Number)
  
(I.R.S. Employer Identification
No.)

2701 KENT AVENUE
WEST LAFAYETTE, INDIANA
  
47906-1382
(Address of principal executive offices)
  
(Zip Code)

Registrant's telephone number, including area code: (765) 463-4527

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))

 
 
 

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
 
On November 12, 2009, the Board of Directors of Bioanalytical Systems, Inc. elected John B. Landis, Ph.D. as a director of the Company.  Dr. Landis was suggested for election to the Board of Directors by Peter T. Kissinger and Candice B. Kissinger in a letter to the Board of Directors dated June 5, 2009.  There is no arrangement or understanding between Dr. Landis and any other persons pursuant to which Dr. Landis was selected as a director.  The Board of Directors has not determined whether Dr. Landis will be named to any Board committees.
 
Item 9.01.             Financial Statements and Exhibits.
 
(d)        Exhibits
 
 
99.1
Bioanalytical Systems, Inc. press release, issued November 18, 2009.

 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Bioanalytical Systems, Inc.
     
Date: November 18, 2009
By: 
/s/ Michael R. Cox
   
Michael R. Cox
   
Vice President, Finance and Administration,
Chief Financial Officer and Treasurer

 
 
 

Exhibit Index
 
Exhibit No.
  
Description
     
99.1
  
Bioanalytical Systems, Inc. press release, issued November 18, 2009.